| Economic Evaluation of New MDR TB Regimens (NCT04207112) | Medecins Sans Frontieres, Netherlands | 2020-10-20 |
| Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care (NCT04062201) | Wits Health Consortium (Pty) Ltd | 2019-08-22 |
| PRACTECAL-PKPD Sub Study (NCT04081077) | Medecins Sans Frontieres, Netherlands | 2019-08-06 |
| Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis (NCT03086486) | Global Alliance for TB Drug Development | 2017-11-21 |
| Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) (NCT02589782) | Medecins Sans Frontieres, Netherlands | 2017-01-01 |
| An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis (NCT02454205) | University of Cape Town | 2015-11-12 |
| Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients (NCT01521364) | University Medical Center Groningen | 2011-12-01 |
| Training Protocol on the Natural History of Tuberculosis (NCT01212003) | National Institute of Allergy and Infectious Diseases (NIAID) | 2011-06-30 |
| Tuberculosis in China (NCT01071603) | National Institute of Allergy and Infectious Diseases (NIAID) | 2010-02-02 |
| TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB (NCT00664313) | Centers for Disease Control and Prevention | 2009-04-01 |
| Linezolid to Treat Extensively-Drug Resistant Tuberculosis (NCT00727844) | National Institute of Allergy and Infectious Diseases (NIAID) | 2008-07-01 |
| A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB) (NCT00685360) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2008-05-08 |